Taysha gene therapies to host key opinion leader webinar on tsha-106 for the treatment of angelman syndrome

Dallas--(business wire)--taysha gene therapies, inc. (nasdaq: tsha), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns) in both rare and large patient populations, today announced it will host a virtual key opinion leader (kol) webinar on tsha-106 for the treatment of angelman syndrome on tuesday, october 26, 2021, from 10:00 a.m. to 1:00 p.m. et. the
TSHA Ratings Summary
TSHA Quant Ranking